Vision

Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration (AMD) is a vision condition involving changes in the retina that can affect visual function and visual acuity. It may also involve changes measured through macular pigment optical density, multifocal electroretinography responses, or the presence of drusen.

A concise starting point for understanding Age-Related Macular Degeneration (AMD) in the context of vision.

1What may help

This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.

What may help

None of these options has good evidence yet. Best evidence first.

1 option:1 not enough evidence

What studies foundSize of effect

Red Light Therapy (Photobiomodulation)practiceNot enough evidence
Too few or too small studies to know if it works.
3 of 5 studies found a benefit; 2 found none.
A meta-analysis of six randomized trials found no significant improvement compared with sham in BCVA, drusen volume, geographic atrophy, central subfield thickness, or microperimetry. Other reviewed reports described improvement in earlier stages or BCVA, so the findings disagree; a 2026 trial enrolled people with early or intermediate dry AMD.
Open the Red Light Therapy (Photobiomodulation) page

The expert view shows every study, dose protocol and source.

What may help

Interventions recorded as helping with this condition1 listed

The best we have, but the evidence is still weak

PracticesRed Light Therapy (Photobiomodulation)CertaintyLowSourceClinical
A meta-analysis of six randomized trials found no significant improvement compared with sham in BCVA, drusen volume, geographic atrophy, central subfield thickness, or microperimetry. Other reviewed reports described improvement in earlier stages or BCVA, so the findings disagree; a 2026 trial enrolled people with early or intermediate dry AMD.
Who was studied
People with a condition
Age Related Macular Degeneration
Alzheimers Disease
Wound Healing Impaired
Xerostomia
Study result
One study reported positive results, one found no significant results on primary outcome but significant improvement in earlier stages; one cohort study showed significant improvement in BCVA.
Open Red Light Therapy (Photobiomodulation)
→

What to avoid

Interventions recorded as making it worse

Nothing in this library is currently recorded as making Age-Related Macular Degeneration (AMD) worse. Coverage is partial, and absence here is not evidence of safety.

Browse the supplements that are written up

How to read the evidence

Evidence tier — overall strength of the evidence for the whole compound

StrongWell established — backed by strong, consistent human research.
ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
LimitedVery limited evidence — treat this as a hypothesis, not proof.
InsufficientNot enough good evidence to draw conclusions yet.

Certainty — how sure we can be that the effect is real

Very highVery sure — strong, consistent evidence
HighFairly sure — consistent evidence from good studies
MediumModerately sure — new studies could change this
LowNot sure — little or mixed evidence
Very lowVery unsure — almost no usable evidence

Source — where the data comes from

Meta-analysisPooled analysis of many trials — the strongest evidence
RCTRandomized controlled trial — a strong human study design
ClinicalA human clinical study
Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
Animal researchStudied in animals, not humans
Community reportsAggregated user reports — anecdotal signal, not evidence
TheoreticalMechanism-based reasoning, not yet tested

Study grade — quality of each underlying study (A best, D weakest)

AHigh-quality — strong, consistent human trials
BGood — solid evidence with some limitations
CModerate — limited, small, or mixed-quality studies
DWeak — preliminary, indirect, or animal-only

Confidence — how strongly the sources back a finding

A 0–100 score from study quality and agreement

Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.

Full write-up

What is it

Evidence-backed options

The options studied for Age-Related Macular Degeneration (AMD) differ in what they measured and how long they were used. Saffron Extract was associated with modest improvement in mfERG responses, including among participants already using AREDS supplements. For Lutein, the reported findings involved 10 or 20 mg/day taken for more than 6 months, with significant improvements in MPOD and visual acuity in AMD patients. These findings do not establish how quickly changes may appear beyond that study period.

Evidence for some other options is more limited or addresses broader formulations rather than a single supplement. Reviews describe improvements in visual functions, less VFMD worsening, and reduced drusen with Coenzyme Q10, but note a notable lack of studies focused solely on Coenzyme Q10. Zinc has been discussed in relation to slowing progression and preserving vision, while evidence for Astaxanthin and Lycopene remains very limited. Lycopene evidence is described as weaker than evidence for lutein/zeaxanthin.

Omega-3 findings are especially important to interpret by outcome: high-dose EPA and DHA supplementation, including 350 mg/day DHA and 650 mg/day EPA in AREDS2 and 840 mg/day DHA and 270 mg/day EPA in NAT2, did not reduce progression to advanced AMD. Vitamin C 500 mg/day and Vitamin E appear as components of AREDS or AREDS2 formulations, but Vitamin C is not established as monotherapy, and the preventive or therapeutic value of Vitamin B3 remains elusive. A clinician can help interpret these options in relation to AMD stage and existing treatment.